Interleukin-6 blockade appeared effective against immune-related adverse events among a small cohort of patients treated with immune checkpoint inhibitors for melanoma, according to study results published in Cancer Cell.
“Immunotherapy with checkpoint inhibitors is currently the best therapeutic strategy for treatment of multiple cancer types. However, durable remission rate with checkpoint inhibitor monotherapy remains low and, therefore, combination strategies for these agents are needed to overcome therapy resistance,” Adi Diab, MD, researcher in the department of melanoma